Loading...
Clinical trials have suggested a modest excess of diabetes among statin users, and the FDA recently issued new guidance on this subject. But how do the risks and benefits of statins stack up in clinical practice? In an analysis from Taiwan, patients who received statins for ≥30 days from 2000 to 2003 were matched with statin-naive patients. Patients with diabetes or histories of myocardial infarction (MI) or revascularization were excluded (patients with coronary heart disease were not excluded).
After median follow-up of 7.2 years, annual diabetes incidence was slightly, but statistically significantly, higher among statin users than among matched controls (2.4% vs. 2.1%). However, major adverse clinical events such as MI, stroke, or in-hos…